Cargando…

Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer

PURPOSES: The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily...

Descripción completa

Detalles Bibliográficos
Autores principales: Hidding, Janine T., Beurskens, Carien H. G., van der Wees, Philip J., Bos, Wilmy C. A. M., Nijhuis-van der Sanden, Maria W. G., van Laarhoven, Hanneke W. M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876252/
https://www.ncbi.nlm.nih.gov/pubmed/29127528
http://dx.doi.org/10.1007/s00520-017-3907-1
_version_ 1783310471642742784
author Hidding, Janine T.
Beurskens, Carien H. G.
van der Wees, Philip J.
Bos, Wilmy C. A. M.
Nijhuis-van der Sanden, Maria W. G.
van Laarhoven, Hanneke W. M.
author_facet Hidding, Janine T.
Beurskens, Carien H. G.
van der Wees, Philip J.
Bos, Wilmy C. A. M.
Nijhuis-van der Sanden, Maria W. G.
van Laarhoven, Hanneke W. M.
author_sort Hidding, Janine T.
collection PubMed
description PURPOSES: The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily life in relation to lymphedema. METHODS: This is a prospective study with measurements before chemotherapy (T0), during chemotherapy before cycle 2 (T1), cycle 4 (T2), and 1 month after completion of treatment (T3). Volume change was monitored using tape measurements. Lymphedema was defined as ≥ 10% volume difference. Linear mixed-effect models were estimated to analyze differences in arm volume and consequences in daily life (total score and domain scores of the Lymph-International Classification of Functioning (ICF) questionnaire) over time and to identify treatment and patient characteristics as predictors for changes in volume. RESULTS: Forty-eight patients completed all measurements. Volume did not change during TAC treatment. One month after treatment, volume was significantly increased compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary lymph node dissection was associated with lymphedema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with and without lymphedema, 1 month after completion (T3), the Lymph-ICF questionnaire showed significant limitations in physical function compared to T0-T2. In patients with lymphedema at T3, a significant association between volume and total score on the Lymph-ICF questionnaire on physical function and mobility activities was observed. CONCLUSIONS: One month after treatment in 12 patients (25%), volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. All patients, but more patients with lymphedema, perceived difficulties in activities in daily life after treatment.
format Online
Article
Text
id pubmed-5876252
institution National Center for Biotechnology Information
language English
publishDate 2017
publisher Springer Berlin Heidelberg
record_format MEDLINE/PubMed
spelling pubmed-58762522018-04-03 Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer Hidding, Janine T. Beurskens, Carien H. G. van der Wees, Philip J. Bos, Wilmy C. A. M. Nijhuis-van der Sanden, Maria W. G. van Laarhoven, Hanneke W. M. Support Care Cancer Original Article PURPOSES: The purposes of this study were to investigate the incidence of lymphedema in patients with breast cancer during and after adjuvant treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC), to identify predictors for development of lymphedema, and to describe consequences in daily life in relation to lymphedema. METHODS: This is a prospective study with measurements before chemotherapy (T0), during chemotherapy before cycle 2 (T1), cycle 4 (T2), and 1 month after completion of treatment (T3). Volume change was monitored using tape measurements. Lymphedema was defined as ≥ 10% volume difference. Linear mixed-effect models were estimated to analyze differences in arm volume and consequences in daily life (total score and domain scores of the Lymph-International Classification of Functioning (ICF) questionnaire) over time and to identify treatment and patient characteristics as predictors for changes in volume. RESULTS: Forty-eight patients completed all measurements. Volume did not change during TAC treatment. One month after treatment, volume was significantly increased compared to T0-T2, and 12 patients (25%) had developed lymphedema. Axillary lymph node dissection was associated with lymphedema (ES 2.9, 95% CI 0.02–5.7; p < 0.05). In patients with and without lymphedema, 1 month after completion (T3), the Lymph-ICF questionnaire showed significant limitations in physical function compared to T0-T2. In patients with lymphedema at T3, a significant association between volume and total score on the Lymph-ICF questionnaire on physical function and mobility activities was observed. CONCLUSIONS: One month after treatment in 12 patients (25%), volume difference increased over 10%. Axillary lymph node dissection was predictive for development of lymphedema. All patients, but more patients with lymphedema, perceived difficulties in activities in daily life after treatment. Springer Berlin Heidelberg 2017-11-10 2018 /pmc/articles/PMC5876252/ /pubmed/29127528 http://dx.doi.org/10.1007/s00520-017-3907-1 Text en © The Author(s) 2017 Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Hidding, Janine T.
Beurskens, Carien H. G.
van der Wees, Philip J.
Bos, Wilmy C. A. M.
Nijhuis-van der Sanden, Maria W. G.
van Laarhoven, Hanneke W. M.
Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title_full Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title_fullStr Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title_full_unstemmed Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title_short Changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (TAC) in patients with breast cancer
title_sort changes in volume and incidence of lymphedema during and after treatment with docetaxel, doxorubicin, and cyclophosphamide (tac) in patients with breast cancer
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5876252/
https://www.ncbi.nlm.nih.gov/pubmed/29127528
http://dx.doi.org/10.1007/s00520-017-3907-1
work_keys_str_mv AT hiddingjaninet changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer
AT beurskenscarienhg changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer
AT vanderweesphilipj changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer
AT boswilmycam changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer
AT nijhuisvandersandenmariawg changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer
AT vanlaarhovenhannekewm changesinvolumeandincidenceoflymphedemaduringandaftertreatmentwithdocetaxeldoxorubicinandcyclophosphamidetacinpatientswithbreastcancer